Aims: To determine the effects of insulin sensitization (IS) and insulin provision (IP) treatment strategies on adipokines associated with cardiovascular disease in patients with type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial (BARI 2D). Methods and results: Changes in adipokine levels were compared in patients with type 2 diabetes mellitus and coronary artery disease randomized to IS (n ¼ 1037) versus IP (n ¼ 1019) treatment strategies in BARI 2D. Circulating concentrations of leptin, adiponectin, monocyte chemoattractant protein-1, tumor necrosis factor-alpha, interleukin 6 and C-reactive protein were evaluated at baseline and one year. IS and IP treatment strategies exerted significant (p < 0.0001) differential effects on: leptin (IS: 0.02% decrease, p ¼ 0.01; IP: 13% increase, p < 0.0001); adiponectin (IS: 73% increase, p < 0.0001; IP: no change, p ¼ 0.52); interleukin 6 (IS: 14% decrease, p < 0.0001; IP: no change, p ¼ 0.68). Changes in monocyte chemoattractant protein-1 and tumor necrosis factor-alpha were not statistically different between groups. C-reactive protein decreased, but the effect was significantly greater in the IS group (-32%, p < 0.0001) than in the IP group (-5%, p ¼ 0.0005). Conclusion: The IS and IP treatment strategies exerted divergent effects on adipokine and inflammatory profile in patients with type 2 diabetes mellitus and coronary artery disease. The IS treatment strategy-induced changes may be more favorable than the IP treatment strategy regarding cardiovascular pathophysiology.
Introduction
Insulin resistance is a common feature of type 2 diabetes (DM2) and obesity, and may underlie the clustering of cardiovascular risk factors. 1 For instance, the unfavorable metabolic (dyslipidemia, hyperglycemia) and cardiovascular (CV) (hypertension, endothelial dysfunction, coagulation abnormalities, impaired fibrinolysis, systemic inflammation) profile develops primarily in obese individuals who are also insulin resistant, 2 suggesting that insulin resistance is key in the development of vascular dysfunction. Indeed, insulin resistance has been associated with ultrasonographically or angiographically assessed atherosclerosis, even in the absence of other risk factors. [3] [4] [5] The pivotal role of insulin resistance in the pathophysiology and CV consequences of DM2 implies that therapeutic differences may exist between therapies for DM2 that improve insulin sensitivity versus those therapies that only increase insulin levels (without affecting insulin sensitivity), even when the same levels of glycemic control are achieved with both therapeutic approaches. For example, the analysis of the SYMPHONY and 2nd SYMPHONY trials showed that in patients with diabetes after acute coronary syndromes, hypoglycemic therapy including only insulin and/or sulfonylurea (insulin provision, IP) was associated with a higher 90-day rate of CV events compared with therapy that included only biguanide and/or thiazolidinedione (insulin sensitizing, IS). 6 In the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial of patients with DM2 and clinically stable, angiographically documented coronary artery disease (CAD), the lowest rate of major CV events was in the group that underwent prompt revascularization plus IS treatment, with borderline statistical significance (p ¼ 0.07). 7 In another analysis of the BARI 2D trial, the IS (but not IP) strategy reduced the endpoints of myocardial infarction and cardiac death/myocardial infarction in patients with DM2 with more severe and extensive CAD. 8 Whether IP and IS exert differential effects in patients with DM2 and CAD on specific metabolic pathways related to CV pathophysiology has not been determined. One attractive hypothesis is that such differential effects may be related to biologically active hormones released by adipose tissue (adipokines). 9 Studies suggest an important role for adipose tissue in the development of insulin resistance, DM2, and CV disease. 9, 10 Insulin resistance is associated with chronic inflammation characterized by increases in pro-inflammatory adipokines (such as leptin, tumor necrosis factor-alpha (TNF-a), monocyte chemoattractant protein-1 (MCP-1)) along with decreases in anti-inflammatory adipokines (such as adiponectin). 11 Many of the adipokines affect insulin sensitivity, while their secretion is also regulated by insulin. This includes leptin and adiponectin, which play a role in energy homeostasis. Thus, concentrations of adipokines may be affected by insulin levels and the magnitude of insulin resistance. In the present study we tested the hypothesis that IS and IP treatment strategies exert differential longitudinal effects on concentrations of selected adipokines in patients with DM2 and CAD.
Methods

BARI 2D trial
The BARI 2D protocol and five-year results were previously published. 7, 12 The study complied with the Declaration of Helsinki. The protocol was approved by the institutional ethics committee of all participating sites and all subjects provided informed consent. BARI 2D had a 2 Â 2 factorial design to simultaneously randomize patients into a cardiac treatment strategy (comparing prompt revascularization and aggressive medical therapy versus aggressive medical therapy alone with deferred revascularization as needed) AND a diabetes treatment strategy (comparing primarily IS versus IP therapy). The goal was for participants to have an HbA1c < 7.0%. If this was not possible using only the drugs within the assigned randomization group, drugs from the alternative group could be used only after maximizing the drugs in the participants' randomized group. The randomization was not blinded, as participants and physicians would know whether they received coronary artery bypass graft (CABG) or percutaneous coronary intervention (PCI), or whether they used injectable insulin. For more details, see the Methods section of the online Supplementary Material. It took approximately six months for the participants to stabilize their treatment strategies.
This ancillary study to BARI 2D was performed to analyze a subset of existing blood samples for selected adipokine and cytokine levels, specifically leptin, adiponectin, MCP-1, TNF-a, interleukin 6 (IL-6) and Creactive protein (CRP). These adipokines/cytokines were selected because of their relationship to both insulin resistance and CV disease.
Sample collection was coordinated by the BARI 2D Fibrinolysis and Coagulation Systems Core Laboratory at the University of Vermont (B Sobel, PI). All samples were analyzed in the Laboratory of Clinical Biochemistry Research at the University of Vermont. IL-6, leptin, TNF-a and MCP-1 were analyzed using a bead-based multiplex assay system (Millipore Adipokine Panel B). Insulin was assayed using a solid phase two-site enzyme immunoassay (ALPCO). Total adiponectin was measured by a validated enzyme-linked immunoassay (R&D Systems) and high sensitivity CRP by Nephelometry (Siemens). The interassay coefficients of variation were between 5.0% and 8.5%. Additional information regarding the sample preservation is in the online Supplementary Methods and Supplementary Table 1S .
Statistical analysis
This study compared IS versus IP randomized treatment groups from the BARI 2D trial. Continuous and categorical variables at baseline were tested using t-tests and chi-square tests, respectively. The adipokine and cytokine measures were skewed. Non-parametric tests such as Kruskal-Wallis or signed tests were used on non-transformed data. Log transformations were used to obtain approximately normal distributions of the skewed variables. The adipokine and cytokine variables were standardized based on the sex-specific log baseline mean and standard deviation (SD). Of the 6590 laboratory values, there were 26 values that were more than five standard deviations away from the mean on the sex-standardized log scale (12 for leptin, 4 for MCP-1, 9 for TNF-a, 1 for IL-6) and were considered missing. The number of outliers removed values that were >5 SD below the mean was 12 for leptin, 2 for MCP-1, 1 for TNF-a and 1 for IL-6, with the remaining outliers being >5 SD above the mean. Two patients with extreme values on blood insulin were also considered missing. A sex-standardized log transformation was used to determine interaction effects and/or mediation effects within linear models. The mediation analysis includes only the adjustment of the mediating variable. Heat maps of the adipokine values were produced using the R function heatmap.3.
The p-values reported are nominal and not adjusted for multiple comparisons.
Results
Of 2368 patients enrolled in BARI 2D, 2056 (87%) contributed a baseline and a year 1 sample. The baseline demographics, medical history and drug usage were balanced between groups (Table 1) . Online Supplementary Table 2S contains the baseline values of the adipokine, lipid, insulin and body weight measures at baseline, stratified by sex. Statistically significant differences between men and women were present for all measures except MCP-1.
The baseline and first year change are reported in Table 2 , with sex-stratified results in the online Supplementary Tables 3AS and 3BS . At baseline, the IS and IP groups had no significant differences. At one year, insulin levels were reduced in the IS group. The direction of change varied significantly between IS and IP treatment strategies for all measures except for MCP-1 and TNF-a. Leptin levels did not change meaningfully in the IS group, but increased by 13% (18.74 to 21.09 ng/ml) in the IP group; adiponectin increased in the IS group by 73% (4.81 to 8.32 mg/ml) and did not change in the IP group; IL-6 decreased in the IS group by 14% (2.31 to 1.98 pg/ ml) and did not change in the IP group. The decrease in CRP was significantly greater in the IS group (32%, 2.01 to 1.37 mg/ml) than in the IP group (5%, 2.23 to 2.12 mg/ml), which is consistent with what was reported previously in BARI 2D. 13 These changes are visualized in the heat maps in the online Supplementary Figure 1S . In Figure 1 , the mean and 95% confidence interval of the IS treatment strategy effect (compared with the IP treatment strategy effect) on the first year change in the sex-standardized log values is graphed separately for men and women. The post-hoc interaction p-value, testing whether the effect of the IS strategy is the same in men as in women, is reported. The MCP-1 and TNFa confidence intervals cross the zero line, indicating that there were no differential effects between IS and IP treatment strategies in either sex. The remaining measures, except for adiponectin, show that patients in the IP treatment strategy had larger increases in the adipokine levels after one year than patients in the IS treatment strategy. For adiponectin, patients in the IS treatment strategy had a larger increase than patients in the IP treatment strategy. The only adipokine where the IS treatment strategy had a statistically different effect in men and women is leptin (p ¼ 0.04).
The percent of the IS treatment strategy effect mediated by the changes in waist circumference and BMI is shown in Table 3 . For mediation, the IS treatment strategy effect on the adipokine measure should be significant, as measured in the 'IS alone' column. The effect of the waist circumference (or BMI) should also be significant when the IS treatment strategy is in the model, as it is for leptin, the leptin/adiponectin ratio, and the leptin/BMI ratio (not shown). As shown, 15% of the effect of the IS treatment strategy on the first year change in leptin, 2.6% of the effect on the first year change in the leptin/adiponectin ratio, and 30% of the effect on the first year change in the leptin/ BMI ratio are due to the first year changes in waist circumference. Similarly, 39% of the effect of the IS treatment strategy on the first year change in leptin, 7.5% of the effect on the first year change in the leptin/adiponectin ratio, and 92% of the effect on the change in the leptin/BMI ratio are due to the first year changes in BMI.
Discussion
Adipose tissue is an endocrine organ capable of releasing biologically active hormones (adipokines), 9 which have significant effects on CV status and regulation of systemic metabolism. 9 In this study we investigated leptin, adiponectin, IL-6, TNF-a, and MCP-1. These adipokines have been implicated in the pathogenesis of CV disease, and therefore changes in the blood concentrations of these adipokines may conceivably influence therapeutic interventions with CV outcome. We demonstrated that, in patients with DM2 and CAD, two therapeutic strategies, IS versus IP, exert differential effects on the adipokine profile after one year of therapy.
Although pathophysiological mechanisms accounting for the observed effects cannot be directly determined based on results in a clinical trial, mechanistic insights can be inferred. The IS and IP treatment strategies exerted differential effects on body weight (a decrease in weight and BMI in the IS group and an increase in the IP group) and body fat distribution (a decrease in waist circumference in the IS group, suggesting a decrease in abdominal fat). Leptin and IL-6 are elevated in the bloodstream in amounts related to the degree of obesity, while adiponectin is paradoxically lower in obesity. 9, 10 The differential effects of the IS and IP strategies on these adipokines may potentially be related to the differential effects on body fat. In the present study, 39% of the effect of the IS treatment strategy on leptin was mediated by body weight/BMI and 15% was mediated by waist circumference, suggesting that part of the observed effects was related to changes in body fat and fat distribution. No such mediation was seen for adiponectin and IL-6, suggesting that those effects and the remainder of the effect on leptin should be ascribed to the specific actions of the IS and IP interventions on concentrations of plasma adipokines. This is consistent with several experimental studies demonstrating direct effects of IS and IP on adipokines. [14] [15] [16] [17] [18] The differential effect of the two therapeutic strategies on adipokine expression may be partly explained by the interactions between insulin and leptin signaling. At cellular level, insulin and leptin signaling pathways cross-talk, and the proteins which contribute to impaired insulin signaling also cause impaired leptin signaling. 19, 20 Therefore, therapeutic strategies that improve insulin sensitivity are likely to improve leptin cellular signaling as well. Considering the role of leptin in energy homeostasis, this may be the underlying mechanism responsible for the observed differential effects between IS and IP on weight. Improvement in leptin sensitivity may also explain the decreases in insulin for the IS strategy, as leptin has been shown to regulate insulin expression. Furthermore, changes in leptin sensitivity may explain the increases in adiponectin with IS strategy, as a recent study showed that leptin increases adiponectin expression and impaired leptin signaling may contribute to paradoxically low adiponectin levels in human obesity. 21 On the other hand, IP strategy provides additional insulin required to maintain optimal levels of glucose, but does not improve leptin sensitivity.
Regardless of the underlying mechanism, the differential effects of IS and IP treatment strategies on leptin, adiponectin, IL-6, and CRP may have potential implications for CV disease. [22] [23] [24] [25] [26] [27] [28] [29] Some biological properties of these adipokines with respect to CV effects and CV outcomes are summarized in the online Supplementary  Table 4S . The effects of the IS and IP treatment strategies on the adipokine profile and CRP levels are consistent with the notion that IS may exert beneficial effects on CV pathophysiology, in contrast to IP. This is also supported by the recent report that, in contrast to the IP strategy, the IS strategy leads to lower plasminogen activator inhibitor type 1 antigen and activity, lower tissue plasminogen activator antigen, and lower fibrinogen, suggesting that IS also exerts profibrinolytic and antithrombotic effects. 13 One potential implication is for the clinical management of patients with DM2 with CAD. The paradigm of using early and aggressive insulin therapy in patients with DM2 has developed. 30 The rationale for this is based on evidence that early insulin therapy may improve glycemic control and prolong beta cell lifespan and function, as well as improve microvascular endpoints. The benefits on macrovascular endpoints have not been demonstrated in all studies, but overall there is evidence to support the link between tight glycemic control and improved macrovascular CV outcomes. Our results suggest potential additional CV benefits of IS therapies beyond glycemic control, which can conceivably be achieved with administration of IS agents. These potential benefits need to be considered in the context of specific recognized side effects associated with some IS agents. 31 Additional clinical studies, focusing on the role of early IS based therapies in the management of patients with DM2 and CAD, are therefore warranted. Furthermore, future studies should also evaluate whether there are any relevant differences between specific IS interventions (e.g. thiazolidinediones versus metformin) or IP interventions (e.g. insulin versus sulfonylureas).
Randomized treatment comparison of one-year change of adipokines by sex
In conclusion, the present study demonstrated that the IS and IP treatment strategies exert divergent effects on the adipokine profile in DM2 patients with CAD. The IS treatment strategy-induced changes in circulating adipokines appear to be more favorable than the IP treatment strategy from the perspective of attenuating the pathogenesis of CV disease.
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